Discovery and combination of new treatments for cancer treatment based on the modulation of epigenetic targets and adenosine receptors
Although the risk of death from cancer is declining over the past decade, its incidence is increasing.
The treatment of cancer in general, and especially in those types of cancer more aggressive, consists of combinations of drugs with different mechanisms of action, in order to be able to eliminate all the cancerous cells. The main problem with these therapies is that in the long run, most patients end up becoming resistant and refractory to therapy. Therefore, it is important to develop new therapies, especially the development of new combined therapies based on different mechanisms of action and that act on different cellular targets, and which aim to reduce the appearance of resistance phenomena.
This project involves the integration of the pharmaceutical development programs of new targets aimed at the treatment of oncological pathologies of Palobiofarma and Oryzon Genomics. This project aims not only to advance the research lines of each of the participating companies with the collaboration of the participating Research Organizations (USC-BioPharma and LEITAT-Biomed), but also to explore the exploration of a possible combined treatment between The epigenetic inhibitors developed by Oryzon and the inhibitors of the adenosine receptors developed by Palobiofarma. The participation of USC and LEITAT in the analysis and development of the compounds of both companies will allow an integrated way of comparing the results from the compounds of each of the companies and thus help to define and quantify more robustly the possible effects Enhancers or synergists of a combination of compounds.
Project Budget: 1’479’659,52 €
Financial Framework: RETOS COLABORACIÓN
Contract number: RTC-2015-3332-1
Start Date: 01/03/2015
End Date: 31/12/2017
Financiado por: FEDER/Ministerio de Ciencia,Innovación y Universidades – Agencia Estatal de Investigación/_Proyecto RTC-2015-3332-1
Objetivo Temático del Programa Operativo: Promover el desarrollo tecnológico, la innovación y una investigación de calidad.